Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Umibecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017.
- 21 Jul 2016 This trial was "discontinued" in Netherlands, according to European Clinical Trials Database.
- 26 Apr 2016 Status changed from recruiting to completed.